Propranolol is an effective topical and systemic treatment option for experimental epidermolysis bullosa acquisita

Propranolol is a ß-adrenoreceptor type 2 (ADRB2) blocker that regulates heart muscle contractions, smooth muscle relaxation and glycogenolysis. In addition, an increasing number of applications in dermatology have been described; most prominently, the use as a first-line treatment for infantile hemangiomas. We here show that propranolol enhances IL-8-induced neutrophil chemotaxis and reduces the release of reactive oxygen species (ROS) after immune complex (IC) stimulation. To obtain further molecular insights into the modulatory effects of propranolol in activated neutrophils, we performed RNA-sequencing of IC-stimulated neutrophils in the absence and presence of the drug.

Source: Journal of Investigative Dermatology - May 21, 2020 Category: Dermatology Authors: Pia St üssel, Katharina Schulze Dieckhoff, Sven Künzel, Veronika Hartmann, Yask Gupta, Georg Kaiser, Wendelien Veldkamp, Gestur Vidarsson, Remco Visser, Saeedeh Ghorbanalipoor, Kazuko Matsumoto, Malin Krause, Frank Petersen, Kathrin Kalies, Ralf J. Ludw Tags: Original Article Source Type: research